LUMIGAN® (bimatoprost ophthalmic solution)
LUMIGAN® 0.01% is indicated for the reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers)1
LUMIGAN® (bimatoprost ophthalmic solution 0.03% MD)
LUMIGAN® (bimatoprost ophthalmic solution 0.03% UD)
What is LUMIGAN® 0.01% and how does it work?
LUMIGAN® 0.01% belongs to a class of drugs known as prostaglandin analogs1
Prostaglandin analogs like LUMIGAN® 0.01% work by increasing aqueous humor outflow through the trabecular meshwork and enhancing uveoscleral outflow.1
LUMIGAN® 0.01% offers a dual mechanism of action1
The dual mechanism of action stimulates aqueous humor outflow via the trabecular meshwork and uveoscleral pathways, which work together to help lower IOP.1
1 – Increases trabecular meshwork outflow1
2 – Increases uveoscleral outflow1
Image adapted from American Academy of Ophthalmology. 2017.2
Copy from LUMIGAN® 0.01% Summary of Product Characteristics. 2022.1
Administration and dosing of LUMIGAN® 0.01%
LUMIGAN® 0.01% offers the convenience of a single once-daily drop.1
One drop should be administered into the affected eye(s) once daily, in the evening.1
The dose should not exceed once daily, as more frequent administration may lessen the intraocular pressure lowering effect.1
LUMIGAN® 0.01% is indicated for the reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers)1
LUMIGAN® 0.01% may not be suitable for some of your patients
LUMIGAN® 0.01% is contraindicated in:1
Patients with hypersensitivity to the active substance (bimatoprost) or any of the excipients (benzalkonium chloride, sodium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate, hydrochloric acid or sodium hydroxide [to adjust pH], and purified water).
Patients who have had a suspected previous adverse reaction to benzalkonium chloride that has led to discontinuation.
Please refer to LUMIGAN® 0.01% Summary of Product Characteristics for full safety information and precautions for use.
LUMIGAN® 0.01% is indicated for the reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers).1
In a 12-month Phase III clinical study approximately 38% of patients treated with LUMIGAN® 0.1 mg/ml eye drops, solution experienced adverse reactions. The most frequently reported adverse reaction was conjunctival hyperaemia (mostly trace to mild and of a non-inflammatory nature) occurring in 29% of patients. Approximately 4% of patients discontinued due to any adverse event in the 12-month study.1
Please refer to LUMIGAN® 0.01% Summary of Product Characteristics for further information on adverse events.